Award
National Heart, Lung, and Blood Institute 5R41HL167254-02
Inducible HMGB1 antagonist for viral-induced acute lung injury.
Recipient
SIGMOVIR BIOSYSTEMS, INC.
Award Amount
$488,080.00
Ceiling
$488,080.00
Awarded
August 12, 2024
Identifier
5R41HL167254-02
Award to SIGMOVIR BIOSYSTEMS, INC. for developing an inducible HMGB1 antagonist to counteract viral-induced acute lung injury by mitigating inflammation and cytokine storm, with potential broad application against respiratory viruses like influenza and SARS-CoV-2.
Description
Development and testing of an adenoviral vector encoding HMGB1 antagonist to treat inflammatory lung diseases caused by various agents, evaluated in murine and cotton rat models.